LLY

952.5

-2.39%↓

JNJ

221.99

-0.09%↓

ABBV

201.13

-0.8%↓

UNH

374.91

+1.99%↑

AZN

182.57

+0.26%↑

LLY

952.5

-2.39%↓

JNJ

221.99

-0.09%↓

ABBV

201.13

-0.8%↓

UNH

374.91

+1.99%↑

AZN

182.57

+0.26%↑

LLY

952.5

-2.39%↓

JNJ

221.99

-0.09%↓

ABBV

201.13

-0.8%↓

UNH

374.91

+1.99%↑

AZN

182.57

+0.26%↑

LLY

952.5

-2.39%↓

JNJ

221.99

-0.09%↓

ABBV

201.13

-0.8%↓

UNH

374.91

+1.99%↑

AZN

182.57

+0.26%↑

LLY

952.5

-2.39%↓

JNJ

221.99

-0.09%↓

ABBV

201.13

-0.8%↓

UNH

374.91

+1.99%↑

AZN

182.57

+0.26%↑

Начало・Списък с акции・Smith & Nephew PLC ADR

Smith & Nephew PLC ADR

Отворен

29.83 -1.03

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

29.54

Максимум

30.24

Ключови измерители
By Trading Economics
Приходи	35M 331M
Продажби	203M 3.2B
P/E Средно за сектора	21.761 49.8
Дивидентна доходност	2.53
Марж на печалбата	10.368
Служители	16,988
EBITDA	133M 856M

Препоръки
By TipRanks
Препоръки	Неутрален
12-месечна прогноза	+10.91% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	2.53% 2.25%

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-2B 13B
Предишно отваряне	30.86
Предишно затваряне	29.83

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

26.64 / 28.37 Подкрепа & съпротива

Smith & Nephew PLC ADR Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

7.05.2026 г., 23:58 ч. UTC

Печалби

OCBC's First-Quarter Net Profit Rose on Record Noninterest Income

7.05.2026 г., 22:57 ч. UTC

Печалби

Australia's Macquarie Beats Consensus With 30% Fiscal Year Profit Jump

7.05.2026 г., 23:52 ч. UTC

Печалби

CoreWeave Stock Dives on Weak Outlook -- Barrons.com

7.05.2026 г., 23:45 ч. UTC

Пазарно говорене

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

7.05.2026 г., 23:39 ч. UTC

Пазарно говорене

Gold Rises on Signs of Ongoing U.S.-Iran Tensions -- Market Talk

7.05.2026 г., 23:28 ч. UTC

Пазарно говорене

Australian Budget Set to Contain A$64B in Spending Cuts-- Market Talk

7.05.2026 г., 23:11 ч. UTC

Печалби

OCBC Group CEO: Well-Positioned to Navigate Uncertainties, Deliver Sustainable Long-Term Value >O39.SG

7.05.2026 г., 23:06 ч. UTC

Печалби

Oversea-Chinese Banking Corp. 1Q Net Interest Margin 1.76%, Down 28 Bps on Year >O39.SG

7.05.2026 г., 23:05 ч. UTC

Печалби

Oversea-Chinese Banking Corp.: Solid 1Q Performance Underpinned by Record Non-Interest Income >O39.SG

7.05.2026 г., 23:04 ч. UTC

Печалби

Oversea-Chinese Banking Corp. 1Q Non-Interest Income S$1.61B Vs. S$1.31B >O39.SG

7.05.2026 г., 23:03 ч. UTC

Печалби

Oversea-Chinese Banking Corp. 1Q Net Interest Income S$2.22B Vs. S$2.35B >O39.SG

7.05.2026 г., 23:03 ч. UTC

Печалби

Oversea-Chinese Banking Corp. 1Q Net S$1.97B Vs. Net S$1.88B >O39.SG

7.05.2026 г., 23:02 ч. UTC

Печалби

Oversea-Chinese Banking Corp. 1Q Total Income S$3.83B Vs. S$3.66B >O39.SG

7.05.2026 г., 23:00 ч. UTC

Пазарно говорене

Australia's Federal Budget Likely to Contain Significant Reforms -- Market Talk

7.05.2026 г., 22:45 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

7.05.2026 г., 22:45 ч. UTC

Пазарно говорене

Lyft Says Efforts to Service Waymo's AVs Are Underway -- Market Talk

7.05.2026 г., 22:42 ч. UTC

Печалби

Australia's Macquarie Beats Consensus With 30% FY Profit Jump

7.05.2026 г., 22:33 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Gilead Stock Falls. A Massive Acquisition Spree Is Coming at a Cost. -- Barrons.com

7.05.2026 г., 22:32 ч. UTC

Печалби

Macquarie FY Total Customer Deposits A$221.5B Vs. A$177.7B>MQG.AU

7.05.2026 г., 22:31 ч. UTC

Печалби

Macquarie FY Return on Equity 14.0% Vs. 11.2%>MQG.AU

7.05.2026 г., 22:31 ч. UTC

Печалби

Macquarie: 68% of FY Income From International >MQG.AU

7.05.2026 г., 22:30 ч. UTC

Печалби

Macquarie Bank Year-End CET1 Level 2 Ratio 12.8%>MQG.AU

7.05.2026 г., 22:30 ч. UTC

Печалби

Macquarie Capital Surplus A$9.3B at March 31 Vs. A$9.5B a Year Earlier>MQG.AU

7.05.2026 г., 22:29 ч. UTC

Печалби

Macquarie CEO: Well-Positioned for Superior Medium-Term Performance>MQG.AU

7.05.2026 г., 22:28 ч. UTC

Печалби

Macquarie: Continues a Conservative Approach to Capital, Funding, Liquidity>MQG.AU

7.05.2026 г., 22:28 ч. UTC

Печалби

Macquarie: Continues to Maintain a Cautious Stance>MQG.AU

7.05.2026 г., 22:27 ч. UTC

Печалби

Macquarie: Decision Recognizes Prevailing Market Conditions>MQG.AU

7.05.2026 г., 22:27 ч. UTC

Печалби

Macquarie Has Not Purchased Shares Since Extending the Buyback>MQG.AU

7.05.2026 г., 22:26 ч. UTC

Печалби

Macquarie to End Share Buyback Extended in November>MQG.AU

7.05.2026 г., 22:25 ч. UTC

Печалби

Macquarie Commodities and Global Markets FY Net Profit Contribution A$4.2B, Up 49% on Year>MQG.AU

Сравнение с други в отрасъла

Ценова промяна

Smith & Nephew PLC ADR Прогноза

Ценова цел

By TipRanks

10.91% нагоре

12-месечна прогноза

Среден 33.56 USD 10.91%

Висок 35.11 USD

Нисък 32 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Smith & Nephew PLC ADR през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Smith & Nephew PLC ADR през последните 3 месеца.

Техническа оценка

By Trading Central

26.64 / 28.37Подкрепа & съпротива

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.